Estudo randomizado | Análise final de eficácia e segurança da vacina de dose única da J&J.
10 Fev, 2022 | 13:53hFinal Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S – New England Journal of Medicine
Comentário no Twitter
A single injection of the Ad26.COV2.S Covid-19 vaccine showed 56.3% vaccine efficacy beginning 14 days after injection and 52.9% efficacy more than 28 days after injection against moderate to severe–critical #COVID19. #IDTwitter https://t.co/0VhaEUtmwq pic.twitter.com/04QqSyYwNI
— NEJM (@NEJM) February 9, 2022